<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180489</url>
  </required_header>
  <id_info>
    <org_study_id>17-7147H</org_study_id>
    <nct_id>NCT03180489</nct_id>
  </id_info>
  <brief_title>Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?</brief_title>
  <official_title>Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christopher Bell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Colorado State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapagliflozin is a medicine to treat diabetes. Its mechanism of action is via sodium-glucose
      co-transporter 2 (SGLT2) inhibition. In adults with diabetes, use of sodium-glucose
      co-transporter 2 inhibitors is associated with moderate weight (fat) loss, in addition to
      other health benefits, including decreased blood pressure, decreased inflammation, and
      decreased oxidative stress. It is unclear as to whether these health benefits are due to
      SGLT2 inhibition per se, or as a secondary effect of weight loss. We wish to compare the
      health benefits of dietary counseling for weight loss with and without concomitant use of an
      SGLT2 inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, prospective, placebo-controlled, double blind, repeated measures study.
      50 overweight/obese adults (body mas index &gt; 27.5 kg/m2) will be recruited for participation
      and randomly assigned to one of two 12 week treatments: (1) daily oral administration of
      Dapagliflozin with dietary counseling to promote weight loss; or, (2) daily oral
      administration of a placebo with dietary counseling to promote weight loss.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Insulin Sensitivity at Week 12 Via Oral Glucose Tolerance Test</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Insulin sensitivity was estimated by measuring circulating insulin concentrations after a 12 hour fast and after ingesting 75 g of glucose. Insulin was measured 0, 30, 60, 90 and 120 minutes after glucose ingestion. Time point 0 minutes is reported below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure at Week 12</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Blood pressure was measured with an automatic machine at baseline. Numbers are reported as systolic/diastolic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Perception of Satiety at Week 12</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Participants answered a satiety questionnaire before liquid meal primer, immediately post liquid meal primer, 60 minutes post liquid primer, immediately post breakfast buffet, 60 minutes, 120 minutes and 180 minutes post breakfast buffet. Responses how full do you feel right now? for 60 minutes post liquid meal primer ingestion are reported below. This was determined by using a visual analog scale. The left side of the analog scale represents a null answer (e.g. How full do you feel right now)? Answer 0: Not full at all. The right side of the line represented the strongest answer in the opposite direction (e.g. How full to you feel right now)? Answer 100: Extremely full. The length of the line is 100 mm, thus the scale ranges for all answers were 0-100. All values are reported as values between 0 and 100. If the answers to the fullness questions increased, this represented a decreased desire to eat.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Perception of Hunger at Week 12</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Participants answered a hunger questionnaire before liquid meal primer, immediately post liquid meal primer, 60 minutes post liquid primer, immediately post breakfast buffet, 60 minutes, 120 minutes and 180 minutes post breakfast buffet. Responses to how hungry do you feel right now? for 60 minutes post liquid meal primer ingestion are reported below. This was determined by using a visual analog scale. The left side of the analog scale represents a null answer (e.g. How hungry do you feel right now? Answer 0: Not hungry at all. The right side of the line represented the strongest answer in the opposite direction (e.g. How full to you feel right now)? Answer 100: Extremely hungry. The length of the line is 100 mm, thus the scale ranges for all answers were 0-100. All values are reported as values between 0 and 100. If the answers to the fullness questions increased, this represented an increased desire to eat.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Marker of Inflammation (High Sensitive C-reactive Protein) at Week 12</measure>
    <time_frame>Data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Marker of Inflammation (Tumor Necrosis Factor Alpha) at Week 12</measure>
    <time_frame>Data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Marker of Inflammation (Interleukin 6) at Week 12</measure>
    <time_frame>data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hunger Hormone Ghrelin at Week 12</measure>
    <time_frame>data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hunger Hormone Peptide Tyrosine Tyrosine at Week 12</measure>
    <time_frame>data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Maker of Oxidative Stress (Oxidized Low Density Lipoprotein) at Week 12</measure>
    <time_frame>Data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Maker of Oxidative Stress (Low Density Thiobarbituric Acid Reactive Substances) at Week 12</measure>
    <time_frame>Data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Satiety Hormone Leptin at Week 12</measure>
    <time_frame>Data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Satiety Hormone Insulin at Week 12</measure>
    <time_frame>Data not collected</time_frame>
    <description>Will be analyzed using a commercially available biochemical assay.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin with dietary counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with dietary counseling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin Tablet</intervention_name>
    <description>Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
    <arm_group_label>Dapagliflozin with dietary counseling</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
    <arm_group_label>Placebo with dietary counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures.

          -  Aged 18-65 years.

          -  No known Type 2 Diabetes

          -  Body mass index greater than or equal to 27.5 kg/m^2

          -  Limited exercise participation (maximum of 3/week regularly scheduled activity
             sessions of &lt; 30 minutes during the previous month).

          -  Completion of a screening visit consisting of medical history, physical examination,
             and 12-lead electrocardiogram and blood pressure assessment at rest and during
             incremental exercise to volitional exhaustion (Note: Subjects with abnormal screening
             values may be eligible if the results are not clinically significant, as judged by the
             investigator or medical monitor)

          -  Agree to abide by the study schedule and dietary restrictions and to return for the
             required assessments

          -  Women of childbearing potential must have negative pregnancy test and be using
             acceptable contraception

        Exclusion Criteria:

          -  Evidence of clinically significant cardiovascular, respiratory, renal, hepatic,
             pulmonary, gastrointestinal, haematological, neurological, psychiatric, or other
             disease that may interfere with the objectives of the study or the safety of the
             subject, as judged by the investigator in agreement with the sponsor or medical
             monitor, have been hospitalized in the past 2 years as a result of these conditions,
             or are receiving pharmacological treatment for these conditions.

          -  Use of prescription drugs (see exceptions listed below) or herbal preparations in the
             2 weeks before study commencement. Prior use of medication or herbal preparations in
             the 4 weeks before study commencement that are intended for weight-loss and/or
             sold/marketed as weight-loss products or may alter metabolism. Permitted Prescription
             Drugs: Birth Control, Less than a 7 day short course of antibiotics. Note: Rifampicin
             is not permitted. Other medicines, such as those for gastroesophageal reflux disease,
             depression, and Over The Counter analgesics and allergy medications,may be allowed,
             but will be approved on a case-by-case basis.

          -  Is currently enrolled in another clinical study for another investigational drug or
             has taken any other investigational drug within 30 days before the screening visit.

          -  Habitual and/or recent use (within 2 years) of tobacco.

          -  Being considered unsuitable for participation in this trial for any reason, as judged
             by the investigator or medical monitor.

          -  History of serious hypersensitivity reaction to Dapagliflozin.

          -  Severe renal impairment, end-stage renal disease, or dialysis.

          -  Pregnant or breastfeeding individual.

          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as
             aspartate aminotransferase (AST) &gt;3x upper limit of normal and/or alanine
             aminotransferase (ALT) &gt;3x upper limit of normal.

          -  Total bilirubin &gt;2.0 mg/dL (34.2 umol/L).

          -  Positive serologic evidence of current infectious liver disease including Hepatitis B
             viral antibody immunoglobulin M, Hepatitis B surface antigen and Hepatitis C virus
             antibody.

          -  Estimated Glomerular Filtration Rate &lt;60 mL/min/1.73 m^2 (calculated by
             Cockcroft-Gault formula).

          -  History of bladder cancer.

          -  Recent cardiovascular events in a patient, including any of the following: acute
             coronary syndrome within 2 months prior to enrolment; hospitalization for unstable
             angina or acute myocardial infarction within 2 months prior to enrolment; acute stroke
             or trans-ischemic attack within two months prior to enrolment; less than two months
             post coronary artery revascularization; congestive heart failure defined as New York
             Heart Association class IV, unstable or acute congestive heart failure. Note: eligible
             patients with congestive heart failure, especially those who are on diuretic therapy,
             should have careful monitoring of their volume status throughout the study.

          -  Blood pressure at enrolment: Systolic blood pressure ≥160 mmHg and/or diastolic blood
             pressure ≥100 mmHg.

          -  Blood pressure at randomization: Systolic blood pressure ≥165 mmHg and/or diastolic
             blood pressure ≥100 mmHg

          -  Individuals who, in the judgment of the medical monitor, may be at risk for
             dehydration.

          -  Individuals with a history of fragility fracture, or bone mineral density values
             reflective of risk for fracture (DEXA Z-score &lt;or= to -2 in pre-menopausal women, and
             men &lt;50, and T-score &lt;or= to -1) will not be permitted to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Bell, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Melby, Dr.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado State University, Dept. of Health and Exercise Science</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80523-1582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <results_first_submitted>December 20, 2019</results_first_submitted>
  <results_first_submitted_qc>January 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2020</results_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Colorado State University</investigator_affiliation>
    <investigator_full_name>Christopher Bell</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03180489/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin With Dietary Counseling</title>
          <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
        </group>
        <group group_id="P2">
          <title>Placebo With Dietary Counseling</title>
          <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin With Dietary Counseling</title>
          <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
        </group>
        <group group_id="B2">
          <title>Placebo With Dietary Counseling</title>
          <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.69" spread="0.08"/>
                    <measurement group_id="B2" value="1.67" spread="0.09"/>
                    <measurement group_id="B3" value="1.68" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.5" spread="15.6"/>
                    <measurement group_id="B2" value="93.8" spread="20.4"/>
                    <measurement group_id="B3" value="95.13" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="3.9"/>
                    <measurement group_id="B2" value="33.2" spread="5.6"/>
                    <measurement group_id="B3" value="33.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116" spread="8"/>
                    <measurement group_id="B2" value="112" spread="10"/>
                    <measurement group_id="B3" value="114" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="5"/>
                    <measurement group_id="B2" value="69" spread="8"/>
                    <measurement group_id="B3" value="69" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak Oxygen Uptake</title>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.2" spread="5.0"/>
                    <measurement group_id="B2" value="24.8" spread="5.6"/>
                    <measurement group_id="B3" value="23.5" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.7" spread="6.9"/>
                    <measurement group_id="B2" value="76.1" spread="7.7"/>
                    <measurement group_id="B3" value="75.4" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Insulin</title>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="0.8"/>
                    <measurement group_id="B2" value="11.1" spread="3.5"/>
                    <measurement group_id="B3" value="9.0" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dietary Intake</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1819" spread="491"/>
                    <measurement group_id="B2" value="2187" spread="541"/>
                    <measurement group_id="B3" value="2003" spread="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carbohydrate</title>
          <units>g/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197" spread="59"/>
                    <measurement group_id="B2" value="246" spread="73"/>
                    <measurement group_id="B3" value="222" spread="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat</title>
          <units>g/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" spread="26"/>
                    <measurement group_id="B2" value="91" spread="28"/>
                    <measurement group_id="B3" value="84" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Protein</title>
          <units>g/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" spread="25"/>
                    <measurement group_id="B2" value="85" spread="24"/>
                    <measurement group_id="B3" value="83" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <units>mL/min/173m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154" spread="52"/>
                    <measurement group_id="B2" value="152" spread="54"/>
                    <measurement group_id="B3" value="153" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Insulin Sensitivity at Week 12 Via Oral Glucose Tolerance Test</title>
        <description>Insulin sensitivity was estimated by measuring circulating insulin concentrations after a 12 hour fast and after ingesting 75 g of glucose. Insulin was measured 0, 30, 60, 90 and 120 minutes after glucose ingestion. Time point 0 minutes is reported below.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Sensitivity at Week 12 Via Oral Glucose Tolerance Test</title>
          <description>Insulin sensitivity was estimated by measuring circulating insulin concentrations after a 12 hour fast and after ingesting 75 g of glucose. Insulin was measured 0, 30, 60, 90 and 120 minutes after glucose ingestion. Time point 0 minutes is reported below.</description>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="0.8"/>
                    <measurement group_id="O2" value="11.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.7"/>
                    <measurement group_id="O2" value="6.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Pressure at Week 12</title>
        <description>Blood pressure was measured with an automatic machine at baseline. Numbers are reported as systolic/diastolic</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at Week 12</title>
          <description>Blood pressure was measured with an automatic machine at baseline. Numbers are reported as systolic/diastolic</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" spread="10"/>
                    <measurement group_id="O2" value="112" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="8"/>
                    <measurement group_id="O2" value="69" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Perception of Satiety at Week 12</title>
        <description>Participants answered a satiety questionnaire before liquid meal primer, immediately post liquid meal primer, 60 minutes post liquid primer, immediately post breakfast buffet, 60 minutes, 120 minutes and 180 minutes post breakfast buffet. Responses how full do you feel right now? for 60 minutes post liquid meal primer ingestion are reported below. This was determined by using a visual analog scale. The left side of the analog scale represents a null answer (e.g. How full do you feel right now)? Answer 0: Not full at all. The right side of the line represented the strongest answer in the opposite direction (e.g. How full to you feel right now)? Answer 100: Extremely full. The length of the line is 100 mm, thus the scale ranges for all answers were 0-100. All values are reported as values between 0 and 100. If the answers to the fullness questions increased, this represented a decreased desire to eat.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Perception of Satiety at Week 12</title>
          <description>Participants answered a satiety questionnaire before liquid meal primer, immediately post liquid meal primer, 60 minutes post liquid primer, immediately post breakfast buffet, 60 minutes, 120 minutes and 180 minutes post breakfast buffet. Responses how full do you feel right now? for 60 minutes post liquid meal primer ingestion are reported below. This was determined by using a visual analog scale. The left side of the analog scale represents a null answer (e.g. How full do you feel right now)? Answer 0: Not full at all. The right side of the line represented the strongest answer in the opposite direction (e.g. How full to you feel right now)? Answer 100: Extremely full. The length of the line is 100 mm, thus the scale ranges for all answers were 0-100. All values are reported as values between 0 and 100. If the answers to the fullness questions increased, this represented a decreased desire to eat.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="16"/>
                    <measurement group_id="O2" value="21" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" spread="18"/>
                    <measurement group_id="O2" value="28" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Perception of Hunger at Week 12</title>
        <description>Participants answered a hunger questionnaire before liquid meal primer, immediately post liquid meal primer, 60 minutes post liquid primer, immediately post breakfast buffet, 60 minutes, 120 minutes and 180 minutes post breakfast buffet. Responses to how hungry do you feel right now? for 60 minutes post liquid meal primer ingestion are reported below. This was determined by using a visual analog scale. The left side of the analog scale represents a null answer (e.g. How hungry do you feel right now? Answer 0: Not hungry at all. The right side of the line represented the strongest answer in the opposite direction (e.g. How full to you feel right now)? Answer 100: Extremely hungry. The length of the line is 100 mm, thus the scale ranges for all answers were 0-100. All values are reported as values between 0 and 100. If the answers to the fullness questions increased, this represented an increased desire to eat.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Perception of Hunger at Week 12</title>
          <description>Participants answered a hunger questionnaire before liquid meal primer, immediately post liquid meal primer, 60 minutes post liquid primer, immediately post breakfast buffet, 60 minutes, 120 minutes and 180 minutes post breakfast buffet. Responses to how hungry do you feel right now? for 60 minutes post liquid meal primer ingestion are reported below. This was determined by using a visual analog scale. The left side of the analog scale represents a null answer (e.g. How hungry do you feel right now? Answer 0: Not hungry at all. The right side of the line represented the strongest answer in the opposite direction (e.g. How full to you feel right now)? Answer 100: Extremely hungry. The length of the line is 100 mm, thus the scale ranges for all answers were 0-100. All values are reported as values between 0 and 100. If the answers to the fullness questions increased, this represented an increased desire to eat.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="25"/>
                    <measurement group_id="O2" value="53" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="20"/>
                    <measurement group_id="O2" value="53" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Marker of Inflammation (High Sensitive C-reactive Protein) at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>Data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Marker of Inflammation (High Sensitive C-reactive Protein) at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Marker of Inflammation (Tumor Necrosis Factor Alpha) at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>Data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Marker of Inflammation (Tumor Necrosis Factor Alpha) at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Marker of Inflammation (Interleukin 6) at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Marker of Inflammation (Interleukin 6) at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hunger Hormone Ghrelin at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hunger Hormone Ghrelin at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hunger Hormone Peptide Tyrosine Tyrosine at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hunger Hormone Peptide Tyrosine Tyrosine at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Maker of Oxidative Stress (Oxidized Low Density Lipoprotein) at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>Data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maker of Oxidative Stress (Oxidized Low Density Lipoprotein) at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Maker of Oxidative Stress (Low Density Thiobarbituric Acid Reactive Substances) at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>Data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maker of Oxidative Stress (Low Density Thiobarbituric Acid Reactive Substances) at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Satiety Hormone Leptin at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>Data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Satiety Hormone Leptin at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Satiety Hormone Insulin at Week 12</title>
        <description>Will be analyzed using a commercially available biochemical assay.</description>
        <time_frame>Data not collected</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin With Dietary Counseling</title>
            <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Dietary Counseling</title>
            <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Satiety Hormone Insulin at Week 12</title>
          <description>Will be analyzed using a commercially available biochemical assay.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected throughout the 12 week intervention period.</time_frame>
      <desc>Subjects were withdrawn are included in the Adverse Event data but are not included in the analysis of the Baseline Characteristics and the Outcome Measures data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin With Dietary Counseling</title>
          <description>Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
Dapagliflozin Tablet: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo With Dietary Counseling</title>
          <description>Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
Placebo Tablet: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Pain and Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache and Dizziness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary Disorders, Yeast Infections and PMS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tooth Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cold Sores</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vitamin D Deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anxiety Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold Symptoms</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E2" events="22" subjects_affected="13" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Joint Soreness and Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Bell</name_or_title>
      <organization>Colorado State University</organization>
      <phone>9704917522</phone>
      <email>christopher.bell@colostate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

